NR4A1 and cancer: However, the two groups in the MF07-01 trial were not well-balanced in terms of subtype as the locoregional treatment group contained more participants with hormone-receptor-positive cancer and less with triple-negative cancer compared with the no locoregional treatment group (85.5% vs. 71.8%, p = 0.01 and 7.3% vs. 17.4%, p = 0.01, respectively).